A study of pazopanib efficacy and safety in patients with advanced clear-cell renal cell carcinoma and ECOG Performance Status 2 (PaZ02).
Phase of Trial: Phase II
Latest Information Update: 13 May 2016
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PaZ02
- 28 Jan 2016 Planned End Date changed from 31 Dec 2015 to 31 Aug 2016, according to United Kingdom Clinical Research Network record
- 28 Jan 2016 Accural to date is 82% according to United Kingdom Clinical Research Network
- 04 Dec 2015 Accrual to date is 80% according to United Kingdom Clinical Research Network.